XPhyto Announces CFO Appointment

Rhea-AI Summary

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) announced the appointment of Mr. Joseph Meagher as Chief Financial Officer. Meagher, a Chartered Professional Accountant with extensive experience in IFRS reporting, is also the CFO at Defence Therapeutics Corp. This follows the previous appointment of Dr. Thomas Beckert as managing director of XP Diagnostics GmbH, indicating a strategic strengthening of XPhyto's leadership. The company focuses on drug delivery and diagnostic innovations across North America and Europe, particularly in regulatory approval for medical products.

Positive

• Appointment of Joseph Meagher as CFO, enhancing financial leadership.
• Experience of Meagher in IFRS reporting and prior CFO roles may strengthen compliance.
• Strategic appointment of Dr. Thomas Beckert indicates focus on drug formulation.

Negative

• None.

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / November 19, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Joseph Meagher as Chief Financial Officer of the Company.

Mr. Meagher is a Chartered Professional Accountant (CPA, CA) and a Chartered Director (C.Dir.). He is currently the CFO of Defence Therapeutics Corp (CSE:DTC), a publicly-traded biotechnology company engineering next generation vaccines and anti-body drug conjugate (ADC) products for precision medicine. Mr. Meagher is highly experienced in IFRS reporting and serves and has served as CFO for several publicly listed companies.

Today's announcement is further to the appointment of Dr. Thomas Beckert as the managing director of XP Diagnostics GmbH, announced November 3, 2021. Prof. Dr. Beckert, a German-based scientist and experienced corporate executive, will be leading XPhyto's drug formulation and diagnostics operations.

Christopher Ross (CPA, CGA) will continue to advise the company on financial and corporate matters, including M&A, valuation work and IFRS compliance and reporting.

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

XPhyto Therapeutics Corp.
Hugh Rogers, CEO and Director

Investor Inquiries:
Mr. Knox Henderson
T: 604-551-2360
E: info@xphyto.com

Forward looking statements

This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: XPhyto Therapeutics Corp.

View source version on accesswire.com:
https://www.accesswire.com/673871/XPhyto-Announces-CFO-Appointment

FAQ

Who is the new CFO of XPhyto Therapeutics?

Mr. Joseph Meagher has been appointed as the Chief Financial Officer of XPhyto Therapeutics.

What is the focus of XPhyto Therapeutics Corp.?

XPhyto focuses on next-generation drug delivery, diagnostics, and pharmaceutical investments.

When was the CFO of XPhyto appointed?

Mr. Joseph Meagher was appointed CFO on November 19, 2021.

Who was appointed managing director at XP Diagnostics GmbH?

Dr. Thomas Beckert was appointed as the managing director of XP Diagnostics GmbH.

What is the stock symbol for XPhyto Therapeutics?

The stock symbol for XPhyto Therapeutics is XPHYF.